LORETTA NASTOUPIL to Lymphopenia
This is a "connection" page, showing publications LORETTA NASTOUPIL has written about Lymphopenia.
Connection Strength
0.177
-
Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (=65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncol. 2022 03; 23(3):406-415.
Score: 0.177